HIV Drug Wholesalers' Attys Get $75M In Gilead Antitrust Case

By Bonnie Eslinger · January 22, 2024, 6:47 PM EST

A California federal judge has given final approval to Gilead Sciences' $247 million settlement with direct purchasers of HIV medications, including an award of $75 million for attorney fees, ending claims...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019

Recent Articles By Bonnie

March 22, 2024
Expert's Sanctions Off Limits In SEC's 'Shadow Trading' Trial
March 11, 2024
Acadia Investors Get Class Cert. In Suit Over Parkinson's Drug
March 08, 2024
Trump 'An Existential Threat' To Rule Of Law, Attys Warn
January 08, 2024
Teva, Israeli Investors End Investor Suit Over Opioid Scandal
January 05, 2024
9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
January 03, 2024
ACTS Retirement Data Breach Suit Settlement Gets Initial OK
December 20, 2023
Calif. County Workers Near Cert. In Vaccine Exemption Suit
December 07, 2023
Bankrupt Drug Treatment Center Takes Cigna Row To 9th Circ.
November 03, 2023
AI Will 'Revolutionize' Class Action Payouts, Judge Says
October 30, 2023
Data Shows Minority Attys 'Woefully' Low On MDL Teams